NanOlogy, LLC, a Texas-based clinical-stage oncology company, has announced the launch of a drug development program focused on diffuse intrinsic pontine glioma, known as DIPG, a universally fatal pediatric brainstem tumor. The company is advancing Large Surface Area Microparticle Cisplatin, or LSAM-cisplatin, designed for stereotactic intratumoral administration in children. Investigational New Drug–enabling studies are underway, with a first clinical trial planned to begin in late 2026, aiming to test safety and response of this new approach where traditional treatments have failed to deliver long-term survival.

Why direct-to-tumor drug delivery could disrupt DIPG’s grim prognosis

For decades, DIPG has remained one of the most resistant challenges in pediatric oncology. Its location in the brainstem and highly infiltrative nature make surgical resection impossible. Systemic therapies, including classic cisplatin, have failed to move the needle on survival outcomes, mainly due to poor drug penetration across the blood-brain barrier and high systemic toxicity. NanOlogy’s LSAM-cisplatin program represents a strategic departure from these constraints by enabling direct, sustained-release chemotherapy at the tumor site itself, with the goal of minimizing harmful effects elsewhere in the body.

What sets LSAM-cisplatin apart from standard chemotherapy in brain tumors

Cisplatin has a long track record as a cytotoxic backbone in solid tumor treatment, but its systemic administration is limited by its inability to cross the blood-brain barrier and its toxic side effects. NanOlogy’s formulation, using large surface area microparticles, is designed for local injection straight into the tumor via stereotactic neurosurgery. The idea is to provide a continuous, concentrated release of cisplatin at the tumor microenvironment, hoping to maximize local efficacy while avoiding the typical toxicities that prevent dose escalation in children. This approach is not just an incremental tweak; it is a reimagining of how, and where, cisplatin is delivered.

How trial design and regulatory scrutiny will define the impact of this program

With Investigational New Drug–enabling studies progressing, regulatory watchers are focused on how NanOlogy will design its first-in-human trial for DIPG. In rare, aggressive diseases with ultra-low survival, regulators sometimes allow accelerated pathways—if safety can be demonstrated and endpoints are clinically meaningful. However, DIPG’s anatomical complexity and high procedural risk mean that demonstrating both the safety and feasibility of intratumoral injections is a steep hurdle. Clinicians in pediatric neuro-oncology will closely examine the trial’s criteria for safety, precision of drug delivery, and early efficacy signals before embracing the approach.

What this shift toward intratumoral therapy reveals about innovation in pediatric oncology

The willingness to attempt direct intratumoral drug delivery in a brainstem tumor reflects a growing belief that new engineering solutions may finally outpace traditional chemotherapy and radiation. Local delivery is now possible in brain tumors thanks to improvements in imaging, neurosurgical accuracy, and particle engineering. Industry observers note that platform technologies such as LSAM are beginning to make old drugs relevant again in areas where the delivery challenge—not the drug mechanism—has historically been the bottleneck. If successful, this trial could trigger renewed interest in repurposing other classic cytotoxics with next-generation delivery platforms.

Why LSAM-cisplatin could be both a model and a cautionary tale for rare brain tumor therapy

While there is considerable optimism about the potential of LSAM-cisplatin, industry analysts are not blind to the program’s risks. Local administration into the brainstem comes with inherent dangers, including risk of tissue damage, uneven distribution, and possible long-term effects on brain function. Moreover, the biological diversity of DIPG means that a single-agent cytotoxic, even delivered directly, may not address the full spectrum of tumor resistance. Scalability could also become a limiting factor, given the technical expertise and resources required for stereotactic administration in pediatric patients. Manufacturing, distribution, and payer adoption for a rare disease therapy are additional hurdles, especially for a privately held company with a focused pipeline.

How NanOlogy’s approach compares with emerging strategies in pediatric brain cancer

NanOlogy’s LSAM-cisplatin is only one of several new strategies being pursued for DIPG. Other developers are working on targeted molecular agents, immunotherapies, and blood-brain barrier disruption techniques, including focused ultrasound and convection-enhanced delivery. Unlike these experimental approaches, NanOlogy’s technology leverages an existing chemotherapeutic agent with a validated mechanism, potentially making it easier to move through early regulatory and clinical milestones. However, many pediatric oncologists have grown skeptical of incremental survival improvements with cytotoxics alone and are likely to look for combinations with molecularly targeted or immune-based agents if LSAM-cisplatin proves safe and effective.

What key challenges could slow clinical and commercial momentum

A major challenge for LSAM-cisplatin is logistical: successful delivery relies on access to specialized pediatric neurosurgery centers with advanced imaging and stereotactic equipment. This could restrict patient access, especially outside major urban academic hospitals. Manufacturing scale and quality control for large surface area microparticle formulations must be demonstrated, along with a clear plan for distribution and training. On the commercial side, rare pediatric indications usually depend on favorable orphan drug status and reimbursement pathways, but even these incentives can fall short if the real-world patient pool is too small or the administration process is too complex.

What industry experts and clinicians will be watching as the program moves forward

Experts tracking pediatric neuro-oncology will focus on the details of trial enrollment, safety signals from early-stage dosing, and evidence that intratumoral LSAM-cisplatin can sustain therapeutic drug levels long enough to impact disease progression. Regulatory reviewers will be watching for precision in delivery, consistency in dosing, and protocols for managing adverse events. Payers and health system stakeholders will need to see real-world data that supports not just efficacy, but also the cost-effectiveness and logistical feasibility of this approach. If early results are positive, NanOlogy could find itself at the center of a much larger conversation about local drug delivery for hard-to-treat cancers.

Is this the beginning of a new chapter for DIPG and local drug delivery?

Industry analysts suggest that even small gains in DIPG survival would represent a real advance for a field that has seen almost no progress for decades. The success of LSAM-cisplatin could pave the way for a new generation of drug delivery innovations in both pediatric and adult oncology, particularly in settings where traditional systemic therapy has hit a wall. Still, the path from preclinical promise to real-world change is littered with failed attempts. The trial’s results—expected after the planned late-2026 start—will ultimately determine whether this bold bet on engineering and direct delivery can deliver meaningful hope for families facing the most devastating diagnosis in pediatric cancer.

Can local innovation overcome DIPG’s historical dead ends?

NanOlogy’s initiative to bring LSAM-cisplatin into the clinic for DIPG is an ambitious and high-stakes experiment in drug delivery science. If the approach is proven to be safe and effective, it could not only change the outlook for DIPG but also inspire a broader rethink of how legacy drugs are used in modern oncology. For now, the field will be watching closely as NanOlogy prepares to take its first steps into clinical testing.

  clinical trials, diffuse intrinsic pontine glioma, DIPG, intratumoral therapy, LSAM-cisplatin, NanOlogy, oncology, pediatric brain tumors